- Home
- IPSC vs RDI Comparison
IPSC vs RDI Comparison
Compare IPSC & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- RDI
- Stock Information
- Founded
- IPSC 2019
- RDI 1937
- Country
- IPSC United States
- RDI United States
- Employees
- IPSC N/A
- RDI N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- RDI Movies/Entertainment
- Sector
- IPSC Health Care
- RDI Consumer Discretionary
- Exchange
- IPSC Nasdaq
- RDI Nasdaq
- Market Cap
- IPSC 43.6M
- RDI 35.7M
- IPO Year
- IPSC 2021
- RDI N/A
- Fundamental
- Price
- IPSC $0.50
- RDI $1.51
- Analyst Decision
- IPSC Strong Buy
- RDI
- Analyst Count
- IPSC 5
- RDI 0
- Target Price
- IPSC $3.33
- RDI N/A
- AVG Volume (30 Days)
- IPSC 603.4K
- RDI 48.7K
- Earning Date
- IPSC 11-04-2025
- RDI 11-13-2025
- Dividend Yield
- IPSC N/A
- RDI N/A
- EPS Growth
- IPSC N/A
- RDI N/A
- EPS
- IPSC N/A
- RDI N/A
- Revenue
- IPSC $114,128,000.00
- RDI $219,213,000.00
- Revenue This Year
- IPSC $1,589.94
- RDI $5.21
- Revenue Next Year
- IPSC N/A
- RDI $11.45
- P/E Ratio
- IPSC N/A
- RDI N/A
- Revenue Growth
- IPSC 5491.77
- RDI 7.59
- 52 Week Low
- IPSC $0.34
- RDI $1.17
- 52 Week High
- IPSC $1.86
- RDI $1.89
- Technical
- Relative Strength Index (RSI)
- IPSC 43.47
- RDI 54.75
- Support Level
- IPSC $0.46
- RDI $1.47
- Resistance Level
- IPSC $0.52
- RDI $1.57
- Average True Range (ATR)
- IPSC 0.03
- RDI 0.07
- MACD
- IPSC 0.00
- RDI -0.01
- Stochastic Oscillator
- IPSC 41.33
- RDI 22.22
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.